Market's view on Abingdon Healt.
Published on April 2024
- Abindon is recovering from the political issues, showing a positive progression.
- Concerns about misleading financial outlooks from Abindon; the company’s indication of a strong second half similar to the previous year does not clarify expected growth rates or financial outflows, raising the possibility of needing additional funding.
- Abindon confirms no additional funding is required, indicating robust current trading conditions and substantial director purchases at higher prices than current share levels.
- SalistickTM, a rapid saliva-based pregnancy test developed by Salignostics, claimed as a first of its kind, has received the CE mark and is seeking FDA approval. This product aims to replace traditional blood and urine tests, offering a non-invasive, hygienic testing method that can be used anywhere.
- Distribution of Salistick is initially to larger shops with plans for wider distribution, which is seen as a positive business development, though availability in smaller outlets is delayed.
- The market potential for Salistick is supported by its competitive pricing compared to existing products and its unique selling proposition (USP), potentially increasing Abingdon’s visibility and credibility in other product lines.